Final CHAMP Trial Results Show Promise for Chemoimmunotherapy in Aggressive Prostate Cancer
Researchers evaluating aggressive-variant metastatic prostate cancer have identified that a specific chemoimmunotherapy regimen was evaluated in the phase 2 CHAMP trial. Presented at the American Society of Clinical Oncology (ASCO) ... Read More